{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:00:37Z","timestamp":1777561237960,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:00:00Z","timestamp":1795219200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.semarthrit.2025.152882","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:09:39Z","timestamp":1763629779000},"page":"152882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Distinct predictors of peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitis: KEIO-vasculitis cohort"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-9810","authenticated-orcid":false,"given":"Yuki","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152882_bib0001","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis-clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0002","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0004","first-page":"e0521","article-title":"Adolescent PR3-ANCA-positive hypertrophic pachymeningitis","volume":"97","author":"Matsumoto","year":"2018","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102940","article-title":"Salivary gland involvement in ANCA-associated vasculitis","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102642","article-title":"Characteristics and prognosis of ANCA-positive retroperitoneal fibrosis: a systematic literature review","volume":"19","author":"Akiyama","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0007","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3389\/fimmu.2019.02617","article-title":"Neutrophil extracellular traps induce tissue-invasive monocytes in granulomatosis with polyangiitis","volume":"10","author":"Akiyama","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0008","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3899\/jrheum.2024-0335","article-title":"Performance of the 2022 ACR\/EULAR classification criteria in comparison with the European Medicines Agency algorithm in ANCA-associated vasculitis","volume":"51","author":"Imai","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0009","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrrheum.2011.184","article-title":"Vasculitis syndromes: peripheral neuropathy in AAV-when vasculitis hits a nerve","volume":"8","author":"Rutgers","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40120-021-00315-7","article-title":"ANCA-Associated Vasculitic Neuropathies: a review","volume":"11","author":"Koike","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0012","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0013","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/acr.20471","article-title":"Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis","volume":"63","author":"Walsh","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RHU.0000000000000713","article-title":"Overall disability sum score for clinical assessment of neurological involvement in eosinophilic granulomatosis with polyangiitis","volume":"24","author":"Padoan","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2024-000938","article-title":"Acute therapeutic effects and pathophysiology of eosinophilic granulomatosis with polyangiitis neuropathy","volume":"7","author":"Yamanaka","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0016","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0018","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1212\/NXI.0000000000000615","article-title":"Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: insights from the DCVAS study","volume":"6","author":"Bischof","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0019","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/jnnp.2006.111013","article-title":"Peripheral neuropathy in Wegener\u2019s granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis","volume":"78","author":"Cattaneo","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3530768","article-title":"Clinical characteristics of peripheral neuropathy in eosinophilic granulomatosis with polyangiitis: a retrospective single-center study in China","volume":"2020","author":"Zhang","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0022","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/biomedicines11030776","article-title":"EGPA phenotyping: not only ANCA, but also eosinophils","volume":"11","author":"Matucci","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0023","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.3390\/biomedicines10112688","article-title":"Baseline eosinophil count as a potential clinical biomarker for clinical complexity in EGPA: a real-life experience","volume":"10","author":"Matucci","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.alit.2020.10.002","article-title":"How to detect eosinophil ETosis (EETosis) and extracellular traps","volume":"70","author":"Fukuchi","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0025","doi-asserted-by":"crossref","first-page":"E1726","DOI":"10.1212\/WNL.0000000000009309","article-title":"Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA","volume":"94","author":"Nishi","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0026","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/art.41727","article-title":"Eosinophil ETosis\u2013Mediated release of galectin-10 in eosinophilic granulomatosis with polyangiitis","volume":"73","author":"Fukuchi","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.801897","article-title":"Increased circulating cell-free DNA in eosinophilic granulomatosis with polyangiitis: implications for eosinophil extracellular traps and immunothrombosis","volume":"12","author":"Hashimoto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0028","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/24725625.2021.1916159","article-title":"Successful early introduction of mepolizumab for peripheral neuropathy with a peripheral circulatory disorder in a patient with myeloperoxidase anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Nishihara","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13223-022-00653-7","article-title":"Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab","volume":"18","author":"Kai","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0030","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2169\/internalmedicine.0613-22","article-title":"Long-term safety and efficacy of Benralizumab for eosinophilic granulomatosis with polyangiitis complicated with severe neuropathy","volume":"62","author":"Koga","year":"2023","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roab005","article-title":"Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis","volume":"32","author":"Nakamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0032","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1146\/annurev-immunol-093019-125918","article-title":"Eosinophil knockout humans: uncovering the role of eosinophils through Eosinophil-directed biological therapies","volume":"39","author":"Jacobsen","year":"2021","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0033","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0034","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus Mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/art.43146","article-title":"Long-term safety and efficacy of Mepolizumab in eosinophilic granulomatosis with polyangiitis","author":"Wechsler","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0036","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41584-025-01266-1","article-title":"Advances in the treatment of ANCA-associated vasculitis","volume":"21","author":"Trivioli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0037","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1212\/NXI.0000000000000407","article-title":"Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis","volume":"4","author":"Takahashi","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflamm"},{"key":"10.1016\/j.semarthrit.2025.152882_bib0038","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-018-0992-4","article-title":"Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study","volume":"19","author":"Ahn","year":"2018","journal-title":"BMC Nephrol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:53:28Z","timestamp":1765979608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225002537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S0049017225002537"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152882","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct predictors of peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitis: KEIO-vasculitis cohort","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152882"}}